Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases

被引：36

作者：

Chung, BH

Lim, SW

Ahn, KO

Sugawara, A

Ito, S

Choi, BS

Kim, YS

Bang, BK

Yang, CW

机构：

[1] Catholic Univ Korea, Xenotransplantat Ctr, Seoul, South Korea

[2] Catholic Univ Korea, Cell Death Res Ctr, Div Nephrol, Dept Internal Med, Seoul, South Korea

[3] Tohoku Univ, Grad Sch Med, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi 980, Japan

来源：

NEPHROLOGY | 2005年 / 10卷

关键词：

diabetic nephropathy; kidney disease; peroxisome proliferator activated receptor-gamma; rosiglitazone;

D O I：

10.1111/j.1440-1797.2005.00456.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Peroxisome proliferator activated receptor gamma (PPAR gamma) agonist has not only antidiabetic effect but also a protective effect against various types of injury of the kidney. The protective effects of PPAR gamma agonists are observed in diabetic nephropathy and non-diabetic renal diseases such as 5/6 ablation model of renal failure, experimental glomerulonephritis, ischemia-reperfusion injury, hypertensive nephropathy and cyclosporin-induced renal injury. The mechanism of renoprotection by PPAR gamma agonist is multifactorial. Anti-fibrotic and anti-inflammatory effects, suppression of renin-angiotensin system, vascular protective effect and antiapoptotic effect were proposed.

引用

收藏

页码：S40 / S43

页数：4

相关论文

共 56 条

[1]

Ando Katsuyuki, 2004, Clin Exp Nephrol, V8, P178

[2] Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation [J].

Asano, T ;

Wakisaka, M ;

Yoshinari, M ;

Iino, K ;

Sonoki, K ;

Iwase, M ;

Fujishima, M .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2000, 1497 (01) :148-154

[3] PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes [J].

Bagi, Z ;

Koller, A ;

Kaley, G .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 286 (02) :H742-H748

[4] Rosiglitazone reduces urinary albumin excretion in type II diabetes [J].

Bakris, G ;

Viberti, G ;

Weston, WM ;

Heise, M ;

Porter, LE ;

Freed, MI .

JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (01) :7-12

[5] Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].

Barroso, I ;

Gurnell, M ;

Crowley, VEF ;

Agostini, M ;

Schwabe, JW ;

Soos, MA ;

Maslen, GL ;

Williams, TDM ;

Lewis, H ;

Schafer, AJ ;

Chatterjee, VKK ;

O'Rahilly, S .

NATURE, 1999, 402 (6764) :880-883

[6] Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse [J].

Beales, PE ;

Liddi, R ;

Giorgini, AE ;

Signore, A ;

Procaccini, E ;

Batchelor, K ;

Pozzilli, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 357 (2-3) :221-225

[7]

BROEDERS N, 2001, KIDNEY INT, V60, P14

[8] A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat [J].

Brown, KK ;

Henke, BR ;

Blanchard, SG ;

Cobb, JE ;

Mook, R ;

Kaldor, I ;

Kliewer, SA ;

Lehmann, JM ;

Lenhard, JM ;

Harrington, WW ;

Novak, PJ ;

Faison, W ;

Binz, JG ;

Hashim, MA ;

Oliver, WO ;

Brown, HR ;

Parks, DJ ;

Plunket, KD ;

Tong, WQ ;

Menius, JA ;

Adkison, K ;

Noble, SA ;

Willson, TM .

DIABETES, 1999, 48 (07) :1415-1424

[9] Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats [J].

Buckingham, RE ;

Al-Barazanji, KA ;

Toseland, CDN ;

Slaughter, M ;

Connor, SC ;

West, A ;

Bond, B ;

Turner, NC ;

Clapham, JC .

DIABETES, 1998, 47 (08) :1326-1334

[10] Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury [J].

Cuzzocrea, S .

VASCULAR PHARMACOLOGY, 2004, 41 (06) :187-195

← 1 2 3 4 5 6 →